Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Dana-Farber reports SAR profile of novel class of antifolates

Oct. 3, 2000

Thymitaq enters phase III for HCC

Oct. 3, 2000

Pfizer transfers anticancer compound to OSI; early trial results released

Oct. 3, 2000

MGI Pharma commences phase II liver cancer trial with irofulven

Oct. 3, 2000

NIH grants anti-Notch-1 monoclonal antibody technology to Viragen

Oct. 3, 2000

Migration-inhibitory peptides identified and investigated at Kyowa Hakko

Oct. 2, 2000

Chugai examines novel enzyme inhibitors as potential anticancer agents

Oct. 2, 2000

Beacon describes preparation and activity of improved butyric acid esters

Oct. 2, 2000

New approach to oncolytic, skin disorders based on specific inhibition of 4-hydroxylase

Oct. 2, 2000

Sigma-Tau selects new camptothecin derivative for preclinical development

Oct. 2, 2000

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...